.RESEARCH STUDY FEATURE.16 October 2024.
In the NIAGARA hearing, the add-on of perioperative durvalumab to conventional treatment for muscle-invasive sac cancer cells strengthened event-free and also generally survival, denoting a new procedure alternative for this health condition.